Home > Boards > US OTC > Miscellaneous > Enzolytics Inc. (ENZC)

Yep! Antibody Production by In Vitro ImmunizationBookmark and Share

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
MC$Trader Member Profile
 
Followed By 25
Posts 1,476
Boards Moderated 1
Alias Born 09/10/20
160x600 placeholder
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/12/2021 7:00:00 AM
CLIS - ClickStream Corp Sees User Growth For Its HeyPal™App Surge, Launch On Android In November Could Create Substantially More Interest InvestorsHub NewsWire - 10/11/2021 10:24:20 AM
CEO Presenting on the Emerging Growth Conference on Tomorrow.  Register Now InvestorsHub NewsWire - 8/17/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on August 4.  Register Now InvestorsHub NewsWire - 8/2/2021 8:27:01 AM
CLIS - ClickStream's HeyPal(TM) App Experiencing Explosive Growth by Reaching Over 3,000,000 Messages, 650,000 Translations, 140,000 Likes, 17,000 Posts and 86,000 Downloads in Just Over 5.5 Months of Beta Launch InvestorsHub NewsWire - 7/28/2021 12:17:04 PM
ALYI Signals VERY BULLISH InvestorsHub NewsWire - 7/23/2021 9:47:41 AM
Enzolytics and Lonza Bioscience ink collaboration agreement Seeking Alpha - 7/21/2021 8:08:36 AM
CEO Presenting on the Emerging Growth / Investors Hub Joint Conference Today! Register Now Niche Companies in Technology, InvestorsHub NewsWire - 7/7/2021 7:00:00 AM
Solar Industry Rollup Continues: Solar Integrated Roofing (SIRC) Targets $100+ Million for 2022, Continues Acquisitions InvestorsHub NewsWire - 6/23/2021 9:16:37 AM
CLS Holdings, (OTCQB: CLSH) $1.9 million Net Revenue for May 87% Increase InvestorsHub NewsWire - 6/15/2021 8:27:38 AM
WNRS Strikes Deal With RSI InvestorsHub NewsWire - 6/14/2021 10:26:26 AM
Enzolytics partners with Intel to co-author a white paper on use of AI in healthcare Seeking Alpha - 5/17/2021 9:53:43 AM
The Emerging Growth Conference is Today April 14 Register now - CEO's Presenting InvestorsHub NewsWire - 4/14/2021 6:30:00 AM
CEO's Presenting on the Emerging Growth Conference on April 14.  Register now. InvestorsHub NewsWire - 4/13/2021 8:18:50 AM
CEO's Presenting on the Emerging Growth Conference on April 14.  Register now. InvestorsHub NewsWire - 4/12/2021 6:47:25 AM
Epazz, Inc. (OTC Pink: EPAZ) Drone Video Release now Live InvestorsHub NewsWire - 3/25/2021 6:00:00 AM
CLS Holdings, (OTCQB: CLSH) $1.49 million Net Revenue for Feb Highest in Company History InvestorsHub NewsWire - 3/9/2021 6:37:33 AM
CLS Holdings, (OTCQB: CLSH) Record January NET Revenue of $1.48 Million Beating Target InvestorsHub NewsWire - 2/9/2021 6:48:48 AM
CLS Holdings, (OTCQB: CLSH) $17 million Sales, 60% Growth & 5 New Products InvestorsHub NewsWire - 2/2/2021 6:52:54 AM
WSGF's, Vaycaychella, Heats Up In $32 Billion Caribbean Vacation Market; Adds Six-Room Hotel To Portfolio Interests InvestorsHub NewsWire - 1/22/2021 9:48:20 AM
Epazz, Inc. (OTC Pink: EPAZ) Enters Blockchain and Cryptocurrency InvestorsHub NewsWire - 1/12/2021 6:00:00 AM
The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think InvestorsHub NewsWire - 1/7/2021 8:00:00 AM
Epazz, Inc. (OTC Pink: EPAZ) Emerging in Blockchain and Cryptocurrency InvestorsHub NewsWire - 1/6/2021 6:00:00 AM
Epazz, Inc. (OTC Pink: EPAZ) Tapping Blockchain & Cryptocurrency with IEO InvestorsHub NewsWire - 12/30/2020 6:00:00 AM
Biotech Companies; Recent Milestones and Potential Upside InvestorsHub NewsWire - 12/22/2020 8:05:00 AM
MC$Trader   Tuesday, 06/08/21 07:32:10 PM
Re: FrankMD post# 112054
Post # of 131591 
Yep! Antibody Production by In Vitro ImmunizationBookmark and Share
With years of extensive experience, Creative Biolabs now is proud to offer the in vitro immunization service for the customize antibodies production. As one of the most efficient immunization strategies, in vitro immunization plays an important role in the monoclonal antibody production.

Introduction of In Vitro Immunization

In the field of biological research, obtaining a high-affinity and high-selectivity antibody is essential for meeting the requirements in diagnostics and therapeutics. As one of the highest efficiency methods, in vitro immunization has taken a series of advantages to establishing the antibody with the desired selectivity and affinity against varies of antigens compared with the conventional immunization method. Through the in vitro immunization, the immune cells will be isolated from the naïve animals and stimulated with the antigen in vitro, this will then result in the induction of B-cells which have the ability to produce the antigen-specific antibodies for the further screening.

In Vitro Immunization-based Human Antibody Production

Creative Biolabs has developed a high-efficiency protocol to induce specific antigen immune response in human peripheral blood mononuclear cells (PBMCs) for the production of human mAbs on the basis of in vitro immunization. The PBMCs which directly isolated from human blood cannot show the sensitization to antigens because of the suppressed function from the immunosuppressive cells such as monocytes and NK cells. However, after the treatment with L-leucyl-L-leucine methyl ester (LLME), the PBMCs are able to initiate the immune response against any antigens as the immunosuppressive cells have been removed. After the in vitro immunization, the antigen-specific antibody genes can be isolated from the library with the help of varies display methods. Combined with our Native™ Human Antibody Discovery Service, Creative Biolabs is able to discovery antigen specific human antibodies with naïve pair heavy- and light-chain.

Features of In Vitro Immunization:

It can bypass ethical limitations to trigger B cells response to antigens of interest. Creative Biolabs can make use of human peripheral blood mononuclear cells to conduct in vitro immunization so that can harvest pure human-originated antibodies to contribute the research within the human body.
It can save the time for evaluating the immune response induced by any antigens during the vaccines test.
Compared to in vivo immunization, in vitro immunization does not have the influence of immunosuppressive and tolerance.
The amount of antigen required for in vitro immunization is greatly reduced.

As a pioneer and the undisputed global leader in the field of antibody production, Creative Biolabs has successfully applied our advanced in vitro immunization service. Depending on novel research methods and tools, we are capable of meeting the specific need of each customer with the best project design. If you are interested in our in vitro immunization service, please do not hesitate to inquire us for more details.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences